Analyst Conference Summaries

Biotechnology Investor Aids

Mylan, Inc.
MYL

conference date: March 1, 2017 @ 10:00 AM Pacific Time

Mylan's Concerns: Debt and Capital Allocation [January 25, 2017 @ Seeking Alpha]

What is $6 in 2017 EPS Worth for Mylan? [February 17, 2016]
Mylan note re Biosimilars [March 11, 2015]
Mylan is Deeply Undervalued [August 27, 2014]

Analyst Call Notes by William P. Meyers
2016
05/03/2016
08/09/2016
11/09/2016
03/01/2017
2015
05/05/2015
08/06/2015
10/30/2015
02/10/2016
2014
05/01/2014
08/07/2014
10/30/2014
 03/02/2015
2013
not available

08/01/2013
10/31/2013 
 02/27/2014

Mylan Pursues Global Generics Dominance Strategy [September 6, 2013]

Mylan (MYL) is a manufacturer of generic drugs and therapies.

Mylan web site
Mylan investor relations page

I took an initial position in Mylan on March 20, 2014

 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMD
 AMGN
 BIIB
 BIND
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 HNSN
 INO
 INTC
 ISRG
 JUNO
 MACK
 MCHP
 MDVN
 MYL.
 NVDA
 OPXA
 PLX
 REGN
 SGEN
 XLNX
 XLRN

 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.

Copyright 2015 William P. Meyers